Maze Therapeutics, Inc. filed a current report on Form 8-K on August 17, 2026, disclosing the appointment of Paula A. Johnson, M.D., M.P.H. and Sophie Kornowski, Pharm.D. to its Board of Directors, effective August 13, 2026.

Key Highlights

  • Two directors appointed: Paula A. Johnson, M.D., M.P.H. joined as a Class III director and Sophie Kornowski, Pharm.D. joined as a Class I director, both effective August 13, 2026.
  • Term lengths differ: Dr. Johnson's term expires at the 2028 annual meeting of stockholders; Dr. Kornowski's term expires at the 2029 annual meeting of stockholders.
  • Committee assignments: Dr. Johnson was appointed to the nominating and corporate governance committee; Dr. Kornowski was appointed to the audit committee and the compensation committee.
  • Option grants issued: Each new director received an option to purchase 36,000 shares of common stock, vesting at 1/36th per month from the appointment date, subject to continued service.
  • Cash retainer: Each director will receive a pro rata portion of the $40,000 annual cash retainer for the remaining portion of the year, plus applicable committee retainers.
  • Board class restructuring: Nancy C. Andrews, M.D., Ph.D. was moved from Class III to Class II, and Hervé Hoppenot was moved from Class II to Class III, to balance class sizes as required by the company's amended and restated certificate of incorporation.

Board Composition and Director Backgrounds at Maze Therapeutics

According to the filing, Maze Therapeutics, Inc. (NASDAQ:MAZE) reported that its Board of Directors appointed two new independent directors on August 13, 2026. Dr. Johnson, age 66, has served as President of Wellesley College since 2016 and previously founded and led the Connors Center for Women's Health and Gender Biology at Brigham and Women's Hospital from July 2002 to June 2016. She has also held faculty positions at Harvard Medical School and the Harvard T.H. Chan School of Public Health, and has served on the board of directors of Johnson & Johnson since 2023. The filing states that the Board believes Dr. Johnson is qualified due to "her extensive leadership experience in academic medicine, public health and higher education."

Dr. Kornowski, age 63, most recently served as Chief Executive Officer of Boston Pharmaceuticals, Inc. from 2022 to 2025, and as a Senior Partner at Gurnet Point Capital from 2018 to 2025, according to the filing. Prior to those roles, she served as Executive Vice-President and Head of Roche Partnering at F. Hoffmann-La Roche AG and as a member of its Extended Corporate Executive Committee. The Board stated it believes Dr. Kornowski is qualified due to "her extensive executive, investment and business development experience in the global biopharmaceutical industry."

In connection with the two appointments, the filing also disclosed that the Board approved a restructuring of its director classes effective August 13, 2026. Dr. Andrews resigned as a Class III director and was immediately reappointed as a Class II director with a term expiring at the 2027 annual meeting, while Mr. Hoppenot resigned as a Class II director and was immediately reappointed as a Class III director with a term expiring at the 2028 annual meeting. The filing states these changes were made so that "each class consists of one-third of the total number of directors," as contemplated by the company's amended and restated certificate of incorporation.

What Was Disclosed

Maze Therapeutics disclosed the appointment of two new directors, their committee assignments, compensation terms including option grants of 36,000 shares each, and a restructuring of board class composition, all effective August 13, 2026.